secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001104659-25-060714
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 2.01, 5.02, 9.01, 2.02, 3.03, 4.01, 5.01, 5.03, 5.05, 5.06, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Crescent Biopharma completes reverse merger with GlycoMimetics; post-merger shares trade under CBIO
--------------------------------------------------------------------------------

- Former GlycoMimetics securityholders own ~2.7% of combined company; Crescent holders own ~97.3% on fully diluted basis.
- Crescent raised ~$200M gross proceeds via pre-closing financing: 85.5M shares and 19.1M pre-funded warrants.
- Exchange ratio set at 0.1445 GlycoMimetics shares per Crescent share; 1-for-100 reverse stock split effected.
- Combined company has ~19.5M shares outstanding (including warrants and convertible preferred) post-merger.
- Company name changed to Crescent Biopharma, Inc.; stock trades under symbol CBIO on Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000110465925060714/0001104659-25-060714-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000110465925060714/tm2518203d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-060714

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer